India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization… Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.” The newly-announced results, when combined with earlier reported data showing that IGC-AD1 reduces Aβ production and inhibits Aβ aggregation without any neuronal toxicity, represent a novel breakthrough toward the treatment of Alzheimer’s, which is known as America’s most expensive disease with an estimated annual cost to the U.S. economy of $236 billion.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More